Paying for Cures research, publications, and media
White papers
Managing the Challenges of Paying for Gene Therapy: Strategies for Market Action and Policy Reform
Emerging market solutions for financing and reimbursement of durable cell and gene therapies
Warranty Model: A potential precision financing solution for durable cell and gene therapies
Payer Perspectives on Financing and Reimbursement of One-time High-cost Durable Treatments
Precision Financing Solutions for Durable / Potentially Curative Therapies
Designing financial solutions to ensure affordable access to cures
Research briefs
Are Cell and Gene Therapy programs a better bet?
Payer perspectives on outcomes tracking for value-based payment arrangements
The resource navigation challenges for patients and caregivers
Updated projection of US durable cell and gene therapies product-indication approvals
Federal Communication Guidelines
Financing Challenges for Solid-Tumor T-Cell Therapies
Pediatric Gene Therapy Launches
Patient-Caregiver Financial Themes
Clinical trials and investment trends for novel CAR-T and TCR therapies
Model Contracts for Innovative Oncology Therapies
Role of COE networks in curative cellular oncology therapies
Stop-Loss Insurance or Reinsurance for Multiyear Contracts
Impact of Patient Mobility on Annuity/Performance-Based Contracting
Orphan Reinsurer Benefit Managers (ORBMs)
Impact of Actuarial Risk on Health Plans
Designing Precision Financing for Cures
Publications
Moradian, R., Meshesha, T., Trusheim, M., & Barlow, J. F. (2024). Payer and Developer perspectives on alternative payment models. Expert Review of Pharmacoeconomics & Outcomes Research, 24(2), 293–301.
Quinn, C., Ciarametaro, M., Sils, B., Phares, S., & Trusheim, M. (2023). Medicaid best price reforms to enable innovative payment models for cell and gene therapies. Expert Review of Pharmacoeconomics & Outcomes Research, 23(2), 191–203.
Young, C. M., Trusheim, M., & Quinn, C. (2022). Data for modelling US projections of product approvals, patients treated, and product revenues for durable cell and gene therapies. Data in Brief, 41, 107891.
C. Young; C. Quinn; M. Trusheim. Durable cell and gene therapy potential patient and financial impact: US projections of product approvals, patients treated, and product revenues. Drug Discovery Today (2021). DOI: 10.1016/j.drudis.2021.09.001
Ivica NA, Young CM. Tracking the CAR-T Revolution: Analysis of Clinical Trials of CAR-T and TCR-T Therapies for the Treatment of Cancer (1997–2020). Healthcare. 2021; 9(8):1062.
J.F. Barlow; M.W. Courtney; M. Trusheim. Payer Perspectives on Gene Therapy Reimbursement. Pharmaceutical Executive, 04/2020
J.F. Barlow; M.W. Courtney; M. Trusheim. Payer Perspectives on Reimbursement of One-Time High-Cost Durable Therapies. Pharmaceutical Executive, 01/09/2020
J.F. Barlow; M. Yang; R. Teagarden. Are Payers Ready, Willing, and Able to Provide Access to New Durable Gene Therapies? Value in Health, 06/2019, 10.1016/j.jval.2018.12.004
J. Barlow; R. Teagarden; M. Trusheim. Precision Financing of Durable, Potentially Curative Therapies. Pharmaceutical Executive, 01/2019
M.R. Trusheim; W.M. Cassidy; P.B. Bach. Alternative State-Level Financing for Hepatitis C Treatment—The "Netflix Model" JAMA, 10/29/2018, 10.1001
D. Han; D.S. Mytelka; G.L. Warren; M. Ciarametaro; M. Trusheim. Improving Management of Gene and Cell Therapies: The Orphan Reinsurer and Benefit Manager (ORBM). PharmaExec.com, 2018
M.R. Trusheim; A.A. Shrier; Z. Antonijevic; R.A. Beckman; R.K. Campbell; C. Chen; K.T. Flaherty; J. Loewy; D. Lacombe; S. Madhavan; H.P. Selker; L.J. Esserman. PIPELINEs: Creating Comparable Clinical Knowledge Efficiently by Linking Trial Platforms. Clinical Pharmacology & Therapeutics, 2016, 10.1002/cpt.514
R. Teagarden; T.F. Unger; G. Hirsch. Access and availability of orphan drugs in the United States: advances or cruel hoaxes? Expert Opinion on Orphan Drugs, 2014, 10.1517/21678707.2014.947265
In the media
April 2024
Better Outcomes Tracking: A First Step In Improving Access To New Treatments
Health Affairs Forefront
November 2023
Value creators or financial destroyers? The potential of gene therapies to transform healthcare
STAT
April 2023
A payment innovation framework to meet the urgent need in advanced therapies
Cell & Gene Therapy Insights
January 2023
Medicaid best price reforms to enable innovative payment models for cell and gene therapies
Expert Review of Pharmacoeconomics & Outcomes Research
May 2022
Aligning Contracting to Solve for Payer Risks Is a Win for Biopharma, Payers, and Patients
Pharmaceutical Executive
February 2022
Contributed to Breakthrough Cures, Blockbuster Costs: Future Directions
Aspen Institute
January 2022
Durable cell and gene therapy potential patient and financial impact: US projections of product approvals, patients treated, and product revenues
Drug Discovery Today
October 2021
Reality Check? Medicaid Costs From Cell, Gene Therapies Projected At (Just) $1Bn-$4Bn By 2030
Pink Sheet
15 September 2021
Medicaid Best Price Volatility Could Inhibit Payment Innovation
Health Affairs Blog
May 2021
NEWDIGS research was cited in "The use of innovative payment mechanisms for gene therapies in Europe and the USA" by Jesper Jørgensen and Panos Kefalas in Regenerative Medicine.
March 2021
Cell and gene therapy: Overview, Current Landscape and Future Trends
The Journal of Precision Medicine
9 December 2020
Gene Therapy Shows Promise for a Form of Blindness, but Is It a Cure? Study of treatment for an inherited form of vision loss raises pricing questions for drugs with long-term benefits
Wall Street Journal
Innovative payment models to support cell and gene therapies on the rise
MedCity News
24 November 2020
Market access of gene therapies across Europe, USA, and Canada: challenges, trends, and solutions
Science Direct: Drug Discovery Today
July 2020
NEWDIGS comment on CMS Proposed Rule supporting Value-Based Purchasing (VBP) (CMS-2482-P) (Download the entire comment)
8 April 2020
Payer Perspectives on Gene Therapy Reimbursement
Pharmaceutical Executive
17 March 2020
U.S. Should Buy Coronavirus Vaccines Before They’re Invented
Bloomberg
February 2020
Gene Therapy: Cures, Risks and Opportunities
Mellon Double Take Podcast
30 January 2020
Managing Uncertainty In Drug Value: Outcomes-Based Contracting Supports Value-Based Pricing
Health Affairs
9 January 2020
Payer Perspectives on Reimbursement of One-Time High-Cost Durable Therapies
Pharmaceutical Executive
12 November 2019
Pharma Panel Grapples With Drug Pricing, Real-World Evidence, and Creating Headroom for Innovative Therapies
Center for Biosimilars
5 September 2019
Insurers Pitch New Ways to Pay for Million-Dollar Therapies
Wall Street Journal
August 2019
Unlocking market access for gene therapies in the United States
McKinsey Insights
23 July 2019
A Need for Precision Financing Methods for Precision Medicines
Going Below the Surface (National Pharmaceutical Council)
15 July 2019
Paying for high-cost drugs like you’d pay a mortgage–and with strings attached
Managed Care
June 2019
Are Payers Ready, Willing, and Able to Provide Access to New Durable Gene Therapies?
18 June 2019
MIT Group Brings Together Stakeholders to Brainstorm How to Pay for Curative Therapies Over Time
American Journal of Managed Care
3 June 2019
Sticker Shock From Breakthrough Therapies Pressures Medicare
Bloomberg Law (registration required)
23 May 2019
New Therapies Offer Possible Cures but Pose Affordability Challenges
American Journal of Managed Care
17 May 2019
Gene Therapies Force Payment Innovation
Specialty Pharmacy Continuum
17 May 2019
Commentary: Novartis CEO: Gene therapy offers hope of cures in one treatment, but US needs new pricing and payment model
CNBC
22 April 2019
When a Treatment Costs $450,000 or More, It Had Better Work
The Atlantic
15 April 2019
Biologics Are Natural Monopolies (Part 1): Why Biosimilars Do Not Create Effective Competition
Biologics Are Natural Monopolies (Part 2): A Proposal For Post- Exclusivity Price Regulation Of Biologics
Health Affairs
15 April 2019
Peter Bach’s latest crazy idea: Give up on biosimilars. Regulate drug prices instead
STAT News
4 April 2019
Value-based agreements could disrupt how we pay for new therapies
STAT News
19 February 2019
Paying for Cures: Ensuring Patient Access and System Sustainability
National Pharmaceutical Council E.V.I.dently Today
19 February 2019
Annuity Payment Model For Cures May Get Test Drive In Massachusetts
Pink Sheet
13 February 2019
Examining New Payment Ideas for Curative Therapies
American Journal of Managed Care
12 February 2019
MIT Releases New Policy and Practice Suggestions to Make Cures Accessible and Sustainable
NEWDIGS Initiative at MIT
12 February 2019
Preparing Patients and the Health System for Curative Therapies in the Pipeline
American Journal of Managed Care
1 February 2019
Focusing on Cures: Payers, Manufacturers, Patients and Academics Are Piloting Financing Options for Curative Therapies
BioCentury
27 January 2019
Precision Financing of Durable, Potentially Curative Therapies
Pharmaceutical Executive
10 January 2019
Louisiana adopts ‘Netflix’ model to pay for hepatitis C drugs
Washington Post
8 January 2019
Biotech Proposes Paying for Pricey Drugs by Installment
Wall Street Journal
19 December 2018
Are Orphan Reinsurance and Benefit Managers the Future of Financing High-Cost Therapies?
AJMC In Focus Blog
20 November 2018
Alternative State-Level Financing for Hepatitis C Treatment—The “Netflix Model”
JAMA Network
14 November 2018
A Search For New Ways To Pay For Drugs That Cost A Mint
NPR
10 September 2018
Improving Management of Gene and Cell Therapies
Pharmaceutical Executive
4 September 2018
Innovating Payment Models For Gene Therapy
First Report Managed Care